Researchers explored the potential of an alternate way to perform PFA on patients with persistent AFib, presenting their findings live at AF Symposium 2024 in Boston.

The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation. 

Heart teams have several options when patients present with stable chest pain and require further testing. According to a brand new analysis of nearly 800 patients, CCTA may be the best place to start. 

New research out of Texas could go a long way toward improving care for patients with acute decompensated heart failure.

The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.

Annual SAVR volumes in the United States decreased by a whopping 44.5% from 2012 to 2022. However, heart teams across the country seem to agree that surgery is a safer, more effective treatment option than TAVR when patients present with bicuspid aortic valves. 

The two neighboring practices have joined forces to provide improved cardiovascular care for patients throughout the Sunshine State. 

Nearly 50% of patients under the age of 60 are now opting for TAVR over SAVR, according to a new study presented at STS 2024 in San Antonio. "We owe it to our patients to take a more prominent role in providing the highest quality evidence to help our patients make these major healthcare decisions," one researcher said.